# Effect of Furosemide on ESWL Outcomes for Renal and Ureteral Calculi

> **NCT05270421** · PHASE3 · UNKNOWN · sponsor: **Shiraz University of Medical Sciences** · enrollment: 500 (estimated)

## Conditions studied

- Urolithiasis
- Nephrolithiasis
- Urinary Calculi
- Ureterolithiasis

## Interventions

- **DRUG:** Furosemide 40 mg
- **OTHER:** Conventional Treatment

## Key facts

- **NCT ID:** NCT05270421
- **Lead sponsor:** Shiraz University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-01
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-07-30
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2022-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05270421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05270421, "Effect of Furosemide on ESWL Outcomes for Renal and Ureteral Calculi". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05270421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*